edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: VolitionRx
Edison Investment Research has terminated coverage on VolitionRx (VNRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.
VolitionRx — 7 videos in collection
Volition (NYSE: VNRX) and Edison recently hosted a webinar in which Volition provided insights into the data it presented at ESICM 2024, highlighting research findings from three large independent studies (over 3,000 patients) on the potential use of Volition’s Nu.Q® NETs H3.1 assay to enhance sepsis management in clinical practice. The webinar explores the role of H3.1 nucleosomes in NETosis and why elevated levels of H3.1 are a cause for concern in sepsis patients, as well as examining how the Nu.Q NETs biomarker could predict organ failure. Volition also gave an update on its commercialisation efforts for Nu.Q NETs.
Get access to the very latest content matched to your personal investment style.